drugset / Trial / NCT01810887

A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants

NCT01810887

Phase 4 Completed 8 enrolled Janssen Pharmaceutical K.K.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (explores what the body does to the drug) and safety of darunavir, and will be administered in combination with Ritonavir in healthy adult Japanese male participants.

Timeline

Start
2008-05
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Darunavir Small molecule 600 mg Oral
Background Ritonavir Other / unclassified 100 mg Oral

Indications

No indication recorded.